Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

Blood

Volumn 118, Issue 8, 2011, Pages 2211-2221

  Gioia, Romain ^a   Leroy, Cédric ^b   Drullion, Claire ^a   Lagarde, Valérie ^a   Etienne, Gabriel ^a   Dulucq, Stéphanie ^a   Lippert, Eric ^a   Roche, Serge ^b   Mahon, François Xavier ^a   Pasquet, Jean Max ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 613606; FOSTAMATINIB; IMATINIB; NILOTINIB; PROTEIN; PROTEIN AXL; PROTEIN CDCP 1; PROTEIN KINASE LYN; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 428; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 80052164672     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-313692     Document Type: Article

References (38)

1. Rowley JD, Testa JR. Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res. 1982;36(1):103-148.
2. Groffen J, Heisterkamp N, Stam K. Oncogene activation by chromosomal translocation in chronic myelocytic leukemia. Cold Spring Harb Symp Quant Biol. 1986;51(Pt2):911-921. (Pubitemid 17078606)
3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375-2384. (Pubitemid 26327486)
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-1082.
6. Burke JR. BMS-345541 is a highly selective inhibitor of I[kappa]B kinase that binds at an allosteric site of the enzyme and blocks NF-[kappa] B-dependent transcription in mice. J Biol Chem. 2003;278(3):1450-1456. (Pubitemid 36801370)
7. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-141. (Pubitemid 40248339)
8. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCRABL, Pgp, or Src kinase overexpression. Cancer Res. 2008;68(23):9809-9816.
9. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070-1079. (Pubitemid 30616875)
10. Leroy C, Fialin C, Sirvent A, et al. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res. 2009;69(6):2279-2286.
11. Robert-Richard E, Richard E, Malik P, Ged C, de Verneuil H, Moreau-Gaudry F. Murine Retroviral but not Human Cellular Promoters Induce In Vivo Erythroid-specific Deregulation that can be Partially Prevented by Insulators. Mole Ther. 2007;15(1):173-182. (Pubitemid 46043663)
12. Zyss D, Montcourrier P, Vidal B, et al. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 2005;65(23):10872-10880. (Pubitemid 41713355)
13. Pocaly M, Lagarde V, Etienne G, et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 2007;21(1):93-101. (Pubitemid 44921840)
14. Perry SE, Robinson P, Melcher A, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. 2007;581(6):1137-1142. (Pubitemid 46385936)
15. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357. (Pubitemid 38072573)
16. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998-1008.
17. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
18. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130(2):177-186. (Pubitemid 32785863)
19. Moroni M, Soldatenkov V, Zhang L, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 2004;64(20):7346- 7354. (Pubitemid 39372073)
20. Bailet O, Fenouille N, Abbe P, et al. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res. 2009;69(7):2748-2756.
21. Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene. 2001;20(30):3969-3978. (Pubitemid 32681602)
22. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-294.
23. Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008;111(7):3821-3829.
24. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016-5031. (Pubitemid 21895263)
25. Neubauer A, Fiebeler A, Graham DK, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994;84(6):1931-1941. (Pubitemid 24286145)
26. Goruppi S, Ruaro E, Varnum B, Schneider C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol. 1997;17(8):4442-4453. (Pubitemid 27318121)
27. Braunger J, Schleithoff L, Schulz AS, et al. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene. 1997;14(22):2619-2631. (Pubitemid 27283101)
28. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23(48): 7957-7968. (Pubitemid 39468854)
29. Paolini R, Molfetta R, Beitz LO, et al. Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of FcεμRI and Syk in RBL Cells. J Biol Chem. 2002;277(40):36940-36947.
30. Swaminathan G, Tsyngankov AY. The Cbl family proteins: Ring leaders in regulation of cell signaling. J Cell Physiol. 2006;209(1):21-43. (Pubitemid 44318665)
31. Caligiuri MA, Briesewitz R, Yu J, et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood. 2007; 110(3):1022-1024. (Pubitemid 47267442)
32. Zimmerman EI, Dollins CM, Crawford M, et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharm. 2010;78(5):811-817.
33. Lay J-D, Hong C-C, Huang J-S, et al. Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL. Cancer Res. 2007;67(8):3878-3887. (Pubitemid 46762176)
34. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CDCP-1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 2007;27(21):7649-7660. (Pubitemid 350033670)
35. Zhang Y-X, Knyazev PG, Cheburkin YV, et al. AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression. Cancer Res. 2008;68(6):1905-1915. (Pubitemid 351416577)
36. Liu L, Greger J, Shi H, et al. Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL. Cancer Res. 2009;69(17):6871-6878.
37. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 2004;10(11):1187-1189. (Pubitemid 39540433)
38. Wu J, Meng F, Kong L-Y, et al. Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. J Natl Cancer Inst. 2008;100(13):926-939. (Pubitemid 351957515)